We have previously developed agonist ligands selectively stimulating the Serotonin 5-HT2A receptor and used in human brain imaging to diagnose patients and evaluate treatments. SAFER will take this to the next level inside the cells by developing the first ‘biased agonists’ able to activate only the desired cellular signal pathway while avoiding side effects. This will help elucidate biological and therapeutic effects and to design safer drugs.
SAFER will provide mechanistic insights and pharmacological tools towards safer treatments for neurological diseases. It comprises University of Copenhagen, Enamine and SARomics Biostructures and PhD students in pharmacology, chemistry, crystallography, computational drug design and scientific database development.
–> Research Overview
MEET THE MEMBERS
SAFER trains five PhD students in pharmacology, chemistry, crystallography, computational drug design and scientific database development. All start at the University of Copenhagen (Denmark), subsequently move to industry: SARomics Biostructures (Sweden) or Enamine (Ukraine) and also have an external Scientific Advisor.
–> View Members
SAFER is composed of:
– University of Copenhagen, Denmark;
– Enamine, Ukraine and
– Saromics Biostructures, Sweden.
Each student will get a PhD degree, and spend at least 1,5 years in industry.
–> See Partners
SAFER is funded by EU’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 765657.